骨钙素不是多发性骨髓瘤进展的标志物。骨髓瘤研究与研究小组（GERM）。

Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myélome (GERM).

作者信息

Mejjad O, Le Loët X, Basuyau J P, Ménard J F, Jego P, Grisot C, Daragon A, Grosbois B, Euller-Ziegler L, Monconduit M

机构信息

Department of Rheumatology, Bois-guillaume Hosptial, University of Rouen, France.

出版信息

Eur J Haematol. 1996 Jan-Feb;56(1-2):30-4.

PMID:8599990

Abstract

The aim of this study was to evaluate the usefulness of serum osteocalcin (OC) levels in multiple myeloma (MM) in order to assess its significance and activity, and to predict its course. Serum OC was measurement in 117 patients with MM and 116 healthy controls matched for age and sex. Serum OC levels were weakly correlated with Karnofsky index (r=0.22; p<0.03). Lowest OC levels were observed when lytic bone lesions increased (p<0.05). There was no relationship between serum OC levels and vertebral crush fractures, serum calcium concentrations or stage of MM, neither was there any relationship between initial serum OC levels and survival. Progression of the disease was associated with a clear fall of serum OC in 61.5% of the "progressive" patients, versus 41% of the persisting "stabilized" cases. Serum OC level was strongly correlated with bone formation (p = 0.005), but not with bone resorption. Serum OC level is a sensitive marker of osteoblast activity, but a poor marker of the severity of MM. We do not consider it as a marker of MM activity or prognosis.

摘要

本研究旨在评估血清骨钙素（OC）水平在多发性骨髓瘤（MM）中的作用，以评估其意义和活性，并预测其病程。对117例MM患者和116例年龄及性别匹配的健康对照者测定血清OC。血清OC水平与卡氏指数呈弱相关（r = 0.22；p < 0.03）。溶骨性骨病变增加时观察到OC水平最低（p < 0.05）。血清OC水平与椎体压缩性骨折、血清钙浓度或MM分期之间均无关联，初始血清OC水平与生存率之间也无关联。在61.5%的“进展期”患者中，疾病进展与血清OC明显下降相关，而持续“稳定期”患者的这一比例为41%。血清OC水平与骨形成密切相关（p = 0.005），但与骨吸收无关。血清OC水平是成骨细胞活性的敏感标志物，但不是MM严重程度的良好标志物。我们不认为它是MM活性或预后的标志物。